CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. - Wikidata - wikimedia - TriplyDB

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

http://www.wikidata.org/entity/Q34279134

about

Cancer-Associated Myeloid Regulatory Cells Genetics and biology of pancreatic ductal adenocarcinoma Key players in pancreatic cancer-stroma interaction: Cancer-associated fibroblasts, endothelial and inflammatory cells Anti-Tumor Immunity in Head and Neck Cancer: Understanding the Evidence, How Tumors Escape and Immunotherapeutic Approaches Exploiting the Immunomodulatory Properties of Chemotherapeutic Drugs to Improve the Success of Cancer Immunotherapy Therapeutic potential of chemokine signal inhibition for metastatic breast cancer Myeloid Cells as Targets for Therapy in Solid Tumors Functional Relationship between Tumor-Associated Macrophages and Macrophage Colony-Stimulating Factor as Contributors to Cancer Progression Targeting cancer with kinase inhibitors Targeting tumor-associated macrophages to combat pancreatic cancer Pro-Tumoral Inflammatory Myeloid Cells as Emerging Therapeutic Targets Genetically engineered mouse models in oncology research and cancer medicine Along the Axis between Type 1 and Type 2 Immunity; Principles Conserved in Evolution from Fish to Mammals T cell exclusion, immune privilege, and the tumor microenvironment Macrophages: An Inflammatory Link Between Angiogenesis and Lymphangiogenesis.Microenvironmental regulation of therapeutic response in cancer Immunotherapy in pancreatic cancer: Unleash its potential through novel combinations.Chemotherapy and tumor microenvironment of pancreatic cancer.Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils.Classification of current anticancer immunotherapies Induction of T-cell Immunity Overcomes Complete Resistance to PD-1 and CTLA-4 Blockade and Improves Survival in Pancreatic Carcinoma.Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment.Bone marrow derived myeloid cells orchestrate antiangiogenic resistance in glioblastoma through coordinated molecular networks.Targeting chemotherapy-induced PTX3 in tumor stroma to prevent the progression of drug-resistant cancers.Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors.Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug.Increased Expression of CSF-1 Associates With Poor Prognosis of Patients With Gastric Cancer Undergoing Gastrectomy.Diverse in vivo effects of soluble and membrane-bound M-CSF on tumor-associated macrophages in lymphoma xenograft model.Co-inhibition of colony stimulating factor-1 receptor and BRAF oncogene in mouse models of BRAFV600E melanoma.Dickkopf-related protein 1 (Dkk1) regulates the accumulation and function of myeloid derived suppressor cells in cancer.Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors Colony stimulating factor 1 receptor inhibition delays recurrence of glioblastoma after radiation by altering myeloid cell recruitment and polarization.IL6 Blockade Reprograms the Lung Tumor Microenvironment to Limit the Development and Progression of K-ras-Mutant Lung Cancer.Overcoming barriers to effective immunotherapy: MDSCs, TAMs, and Tregs as mediators of the immunosuppressive microenvironment in head and neck cancer.CD40 Stimulation Obviates Innate Sensors and Drives T Cell Immunity in Cancer.Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy.Antagonizing Integrin β3 Increases Immunosuppression in Cancer.Transformation of the tumour microenvironment by a CD40 agonist antibody correlates with improved responses to PD-L1 blockade in a mouse orthotopic pancreatic tumour model.Tasquinimod modulates tumor-infiltrating myeloid cells and improves the antitumor immune response to PD-L1 blockade in bladder cancer

P2860

Q26750382-0324D8D2-A63A-46B1-A12F-4192C7A11B04 Q26765438-5FF9DFB0-D908-49C0-88A8-8F4871F7C528 Q26766065-DD18889E-B90B-4AB0-956F-12E19E9618B5 Q26774312-EFEDD895-CEAC-4080-B830-4C2F3165CC89 Q26779184-B6673867-EC08-407C-8381-4E840337BA2E Q26798116-48E85678-4BAE-4319-99C6-BDD892ED9B92 Q26801832-2205BC76-DF25-47C3-83CF-A33F9CF5DD7C Q26863784-333359C5-0925-4BF3-A936-F85F78B24D26 Q26865765-E30EC89B-E9FE-4F1C-863E-492E4E885529 Q28076103-70E035F0-300F-412F-8F69-0CCC7E6644FB Q28076161-A99B21C5-11A7-4ABC-BCCF-D349CE6B31BA Q28079323-4645CF66-1AA4-4F9A-BE8F-05CA274FF11C Q28083360-66B9D05C-61CB-42BE-806B-42F3926D7210 Q28259872-D227B5B5-688D-4E55-BC20-25022DEA5692 Q30278005-B779D43C-5D39-45BA-A81C-836967952316 Q33654609-38A32195-B822-48C2-8037-CEA98DDCC5B1 Q33779875-2C370D15-5A32-4D15-8434-78DB2305C717 Q33876637-68A15C34-7B20-4BC7-A07B-27F991F8B841 Q35090032-D4A7FEDF-0673-4B1C-8BE4-71A21A8035D1 Q35149637-26C4BC5D-DAA3-46EC-84A9-29B259C2D9A5 Q35329190-309D0780-53C2-415D-8ECE-7ADCD85A222E Q36125878-9EC8CA5B-7414-4661-A40E-92B608A3EF1D Q36320144-0F42FC81-0401-44AF-A01E-45523D1A016F Q36390700-FC8A2C3D-553A-4797-8A83-582200166A67 Q36414357-D2C4CF5B-4E22-4D51-B973-14DE7339829F Q36436992-10F2CB82-B9A5-4892-B0DA-7F21C97D5116 Q36459188-6A375ECD-2186-4158-8518-DEE827D6F463 Q36663831-FF62D8B2-1F08-479D-8D94-A96B27686E2D Q36738826-E72E3FE0-6764-4A0E-8958-1D0CDDD132ED Q36821239-2DFBC080-27B7-4449-8B55-86DD81453189 Q36863121-B7196EF3-2558-455E-9F09-4F2C58C28A3E Q36869880-85C2E582-0D5C-4567-9E8B-4E8128E5568F Q36893213-6D2A61DE-ABB5-469D-A51F-DDD445FD1430 Q36963605-BFD62A08-A753-4835-8ACA-8B2D7B3C315D Q37017190-AD154022-6534-4545-A72B-B6C7C057E0D8 Q37029731-3F6EA086-41C6-488C-81BE-C30986A6063D Q37072889-7AD8FFD0-F798-4DEA-822A-88BCD0EEB247 Q37094368-8E292B4A-833B-4070-8E6B-A87F5CDC27D6 Q37109800-18CCC22F-30DF-4C08-AC4B-4D973A1058FD Q37113485-FD55EFC4-0C2E-4E9E-9540-E582135A0324

P2860

CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models.

http://www.wikidata.org/entity/Q34279134

description

2014 nî lūn-bûn

@nan

2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

CSF1/CSF1R blockade reprograms ...... y in pancreatic cancer models.

@ast

CSF1/CSF1R blockade reprograms ...... y in pancreatic cancer models.

@en

CSF1/CSF1R blockade reprograms ...... y in pancreatic cancer models.

@nl

type

label

CSF1/CSF1R blockade reprograms ...... y in pancreatic cancer models.

@ast

CSF1/CSF1R blockade reprograms ...... y in pancreatic cancer models.

@en

CSF1/CSF1R blockade reprograms ...... y in pancreatic cancer models.

@nl

prefLabel

CSF1/CSF1R blockade reprograms ...... y in pancreatic cancer models.

@ast

CSF1/CSF1R blockade reprograms ...... y in pancreatic cancer models.

@en

CSF1/CSF1R blockade reprograms ...... y in pancreatic cancer models.

@nl

P1433

Q34279134-7B509CED-942A-4B8E-949D-590F62B59FD2

P1476

Q34279134-5C3F29FB-F51E-4A77-9F53-033568D44BC7

P2093

Q34279134-1D05CDCE-D67C-49D3-94B2-CA599924232C

Q34279134-1FC5BDE3-D653-4AB7-89C7-308E11417D50

Q34279134-4FDFC9AE-3C83-43D4-8A83-D021571B2D62

Q34279134-7F4117B1-2BBE-4558-8DEB-EB0B09018D21

Q34279134-82CA94DB-8167-4C93-A66D-D5B99B0B8F3A

Q34279134-AE194610-3AA5-4773-ADF1-4FA845FC4D7D

Q34279134-C418B2A6-7543-4A0B-8789-3969E92E86F3

P2860

Q34279134-066A348E-81DF-4001-B72F-DBB261D4E05F

Q34279134-0C6FE8F5-BD50-4F8F-89ED-504ECE2EFB85

Q34279134-13D658C4-B2D5-4696-994F-1B0548ECADF5

Q34279134-1740E367-DA7C-4825-954E-BD6A76C73BE5

Q34279134-1A4B9FBE-4876-48B2-9EDF-D16B70363CE8

Q34279134-24249576-86B0-4DA9-A453-18D34741B980

Q34279134-27D353CC-70AF-43AB-8036-67832B8B4FC2

Q34279134-3652A474-FECD-4ED5-80C5-47BD9C1750D1

Q34279134-3AC475DA-C588-4395-99BB-8B092F438E80

Q34279134-3B794915-753E-4D3B-855F-59DD211D8A43

P304

Q34279134-562AD73D-1AD1-4360-9DA2-09D0BBA19BFF

P31

Q34279134-7030EC03-8570-40C3-AC8A-2B827477DAB4

P356

Q34279134-D4065C90-9E5B-4E05-8D45-8B4804BE86AA

P407

Q34279134-43BB399A-370D-4077-8B8D-50098EFC4BD3

P433

Q34279134-B4710C01-43E0-4123-99D6-7FAA73D67E67

P478

Q34279134-64DA8793-221E-4523-8251-A2BAB81490D7

P50

Q34279134-14B9E7CD-1CD9-4A50-B6AD-16C6FB7C0914

Q34279134-36067707-ED82-462D-984E-0A64BFD34262

Q34279134-6F826371-62B4-46C1-9B48-F887200B1A7F

P577

Q34279134-49008174-FCF2-4A21-A227-1C8838835FF1

P698

Q34279134-11ECF380-6004-4CAB-B4BC-006B679363D9

P921

Q34279134-4F05995D-2497-4AA8-856A-1103A56CF5D4

P932

Q34279134-46ABDDCC-B8A2-4FFB-AAC2-45209BB1DC5C

P356

0008-5472.CAN-13-3723

P1433

Cancer Research

P1476

CSF1/CSF1R blockade reprograms ...... py in pancreatic cancer models

@en

P2093

Andrea Wang-Gillam

http://www.w3.org/2001/XMLSchema#string

Brett L Knolhoff

http://www.w3.org/2001/XMLSchema#string

David C Linehan

http://www.w3.org/2001/XMLSchema#string

David G DeNardo

http://www.w3.org/2001/XMLSchema#string

Jingqin Luo

http://www.w3.org/2001/XMLSchema#string

S Peter Goedegebuure

http://www.w3.org/2001/XMLSchema#string

Timothy M Nywening

http://www.w3.org/2001/XMLSchema#string

P2860

MUC1 enhances invasiveness of pancreatic cancer cells by inducing epithelial to mesenchymal transition

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

Exploring the full spectrum of macrophage activation

Nivolumab plus ipilimumab in advanced melanoma.

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Macrophages, innate immunity and cancer: balance, tolerance, and diversity

Alternative activation of macrophages: an immunologic functional perspective

Macrophage diversity enhances tumor progression and metastasis

Macrophage activation and polarization

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy

P304

5057-5069

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/0008-5472.CAN-13-3723

http://www.w3.org/2001/XMLSchema#string

P407

P433

18

http://www.w3.org/2001/XMLSchema#string

P478

74

http://www.w3.org/2001/XMLSchema#string

P50

Melissa A Meyer

P577

2014-07-31T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25082815

http://www.w3.org/2001/XMLSchema#string

P921

P932

4182950

http://www.w3.org/2001/XMLSchema#string